Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: RETRACTED ARTICLE: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via inhibiting the AMPK–Mfn2 signaling pathway

Fig. 3

Mitochondrial function is inhibited by sorafenib treatment via LATS2. a, b Mitochondrial membrane potential was determined via JC-1 probe. Red-to-green fluorescence ratio was used to quantify mitochondrial membrane potential. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. c, d Flow cytometry was used to observe the ROS accumulation in response to sorafenib treatment and/or LATS2 overexpression. e–g ELISA assay for cellular antioxidants. SOD, GSH and GPX were measured in HepG2 cells treated with sorafenib and/or infected with Ad-LATS2. h ATP production was measured. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us